Differential Expression of Cytokines and Chemokines in Human Monocytes Induced by Lipid Formulations of Amphotericin B
Open Access
- 1 April 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (4) , 1397-1403
- https://doi.org/10.1128/aac.49.4.1397-1403.2005
Abstract
The immunomodulatory effects of liposomal amphotericin B (LAMB), amphotericin B lipid complex (ABLC), and amphotericin B colloidal dispersion (ABCD) on mRNA and protein profiles of five cytokines and chemokines expressed by human monocyte-enriched mononuclear leukocytes (MNCs) were comprehensively evaluated by semiquantitative reverse transcription-PCR and enzyme-linked immunosorbent assays; they were compared to those of deoxycholate amphotericin B (DAMB). mRNAs of interleukin-1β (IL-1β), IL-1 receptor antagonist (IL-1ra), tumor necrosis factor alpha (TNF-α), monocyte chemotactic protein 1 (MCP-1), and macrophage inflammatory protein 1β (MIP-1β) were assessed after treatment of MNCs with each drug for 0.5, 2, 6, and 22 h. The cytokine protein profiles were obtained after incubation of MNCs with the drugs for 2 h (TNF-α) or 6 h (all the others). In the mRNA studies, DAMB resulted in an early increase of inflammatory cytokines or chemokines IL-1β, TNF-α, MCP-1, and MIP-1β (2 to 6 h) and in a late increase of anti-inflammatory IL-1ra (22 h). ABCD showed a general similar trend of inflammatory gene up-regulation. LAMB and ABLC decreased or did not affect IL-1β and TNF-α, whereas ABLC additionally decreased MIP-1β. In protein measurement studies, DAMB and ABCD up-regulated production of IL-1β (P < 0.05), decreased the IL-1ra/IL-1β ratio, and up-regulated the production of MCP-1 and MIP-1β. In comparison, LAMB and ABLC down-regulated or did not affect the production of these cytokines/chemokines compared to untreated MNCs; furthermore, ABLC tended to increase the IL-1ra/IL-1β ratio. These studies demonstrate that amphotericin B formulations differentially affect gene expression and release of an array of proinflammatory and anti-inflammatory cytokines that potentially may explain the differences in infusion-related reactions and dose-dependent nephrotoxicity as well as modulation of the host immune response to invasive fungal infections.Keywords
This publication has 49 references indexed in Scilit:
- Antibody Array-Generated Profiles of Cytokine Release from THP-1 Leukemic Monocytes Exposed to Different Amphotericin B FormulationsAntimicrobial Agents and Chemotherapy, 2004
- Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literatureCurrent Medical Research and Opinion, 2004
- Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer TherapyJournal of Clinical Oncology, 2003
- A Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised PatientsClinical Infectious Diseases, 2002
- Amphotericin B Induces Expression of Genes Encoding Chemokines and Cell Adhesion Molecules in the Human Monocytic Cell Line THP‐1The Journal of Infectious Diseases, 2000
- Amphotericin B–Induced Interleukin‐1β Expression in Human Monocytic Cells is Calcium and Calmodulin DependentThe Journal of Infectious Diseases, 1999
- Amphotericin B Activation of Human Genes Encoding for CytokinesThe Journal of Infectious Diseases, 1998
- Interleukin-4 suppresses antifungal activity of human mononuclear phagocytes against Candida albicans in association with decreased uptake of blastoconidiaFEMS Immunology & Medical Microbiology, 1997
- Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levelsMycoses, 1995
- Pretreatment Regimens for Adverse Events Related to Infusion of Amphotericin BClinical Infectious Diseases, 1995